Competitively inhibits IL-1 binding to the IL-1 type I receptor. Increased IL-1 concentrations have been reported in COVID-19 patients. IL-1a and IL-1b have been implicated in severe COVID-19 disease. This evidence concerns the gene IL1B and COVID-19.